top of page
Coenzyme A overview

Coenzyme A Structure, Biosynthesis, and Metabolic Functions 

Overview of Coenzyme A 

Coenzyme A (CoA) is an essential and ubiquitous cofactor required by all living organisms for a vast array of enzymatic reactions.¹ ² ³ Discovered in 1945 by Fritz Lipmann, who received the Nobel Prize in 1953 for identifying it as the heat-stable factor required for acetylation, CoA is now recognized as a "textbook classic" currently undergoing a research renaissance.¹ ⁴ ⁵ While its fundamental role in carrying activated acyl groups is well-established, modern science has revealed CoA to be a critical regulator of signal transduction, gene expression, and antioxidant defense.¹ ⁶ It is conservatively estimated that CoA and its thioester derivatives participate in approximately 4% to 9% of all cellular enzymatic reactions.¹ ² ⁷

Molecular Structure of Coenzyme A 

The molecular architecture of CoA is uniquely designed for high chemical reactivity, consisting of a 3’-phosphorylated adenosine 5’-diphosphate (ADP) moiety linked to a pantetheine tail derived from vitamin B5 (pantothenic acid).¹ ⁸ ⁹ The functional heart of the molecule is the terminal highly reactive thiol (-SH) group, which forms high-energy thioester bonds with carboxylic acids, effectively activating them for metabolic reactions.¹ ⁹ ¹⁰ CoA is a bulky,negatively charged molecule that is generally membrane-impermeable.¹ ¹¹ Recent biophysical studies have demonstrated that a significant fraction of CoA is bound to magnesium (Mg²⁺) in a 1:1 stoichiometry, particularly in the mitochondria, which modulates the molecule's conformational landscape.¹²

The Biosynthesis of Coenzyme A 

In eukaryotes, CoA is primarily produced through a universal five-step de novo pathway primarily located in the cytosol:

​

1. Pantothenate kinase (PanK): The rate-limiting step that phosphorylates vitamin B5. 

2. Phosphopantothenoylcysteine synthetase (PPCS): Condenses the intermediate with cysteine. 

3. Phosphopantothenoylcysteine decarboxylase (PPCDC): Converts the intermediate into 4’-phosphopantetheine. 

4. Phosphopantetheine adenylyltransferase (PPAT): Transfers an adenylyl group from ATP. 

5. Dephospho-CoA kinase (DPCK): Catalyzes the final phosphorylation to yield active CoA.¹ ¹³ ¹⁴

​

Beyond this canonical route, cells can utilize an alternative salvage route to acquire exogenous CoA.¹⁵ ¹⁶ Extracellular CoA is hydrolyzed by ectonucleotide pyrophosphatases (ENPPs) into stable 4’-phosphopantetheine, which can cross cell membranes via passive diffusion and be converted back into CoA by the bifunctional enzyme CoA synthase (COASY).¹⁵ ¹⁷

Functions of Coenzyme A in Metabolism 

As the master carrier of acyl groups, CoA is indispensable for over 100 biochemical reactions, including the Krebs (TCA) cycle, fatty acid metabolism, and the synthesis of cholesterol, ketone bodies, and neurotransmitters.¹ ² ¹⁸

​

  • Gene regulation: CoA derivatives such as acetyl-CoA and crotonyl-CoA serve as substrates for the post-translational modification of histones, thereby directly modulating the epigenome and gene expression.¹ ¹³ ¹⁹

  • Antioxidant defense: A novel function termed "Protein CoAlation" occurs during oxidative stress, where CoA covalently attaches to cysteine thiols on proteins. This reversible modification protects essential enzymes from irreversible damage and regulates their activity in response to the cellular redox state.⁶ ²⁰ ²¹

  • Protein activation: CoA provides the 4'-phosphopantetheine group required for the activation of mitochondrial acyl carrier protein (mtACP), which is essential for iron-sulfur cluster assembly and lipoic acid metabolism.²² ²³

Diseases Associated with Coenzyme A Dysfunction

Dysregulation of CoA homeostasis is linked to several severe human pathologies:

​

  • Neurodegeneration: Mutations in PANK2 and COASY genes cause Pantothenate Kinase-Associated Neurodegeneration (PKAN) and CoPAN, respectively, which are subgroups of Neurodegeneration with Brain Iron Accumulation (NBIA).¹ ⁶ ¹⁵

  • Cardiac disease: Genetic deficiency in PPCS or PPCDC is a known cause of dilated cardiomyopathy (DCM), a severe heart condition often fatal in early childhood.²⁴ ²⁵

  • Transporter defects: Mutations in SLC25A42, the mitochondrial CoA transporter, cause developmental delays and lactic acidosis; clinical stabilization has been observed following high-dose pantothenic acid supplementation.²⁵ ²⁶

  • Drug discovery: Because microbial and human biosynthetic enzymes differ significantly, the CoA pathway is a primary target for developing novel antibiotics and antimalarial drugs.¹ ¹⁵ ²⁷

References

  1. Theodoulou, F. L., et al. Coenzyme A and its derivatives: renaissance of a textbook classic. Biochem. Soc. Trans. 2014, 42 (4), 1025–1032. 

  2. Srinivasan, B., et al. Coenzyme A, more than ‘just’ a metabolic cofactor. Biochem. Soc. Trans. 2014, 42 (4), 1075–1079. 

  3. Semelak, J. A., et al. binding to coenzyme A. Arch. Biochem. Biophys. 2025, 763, 110202. 

  4. Mouterde, L. M. M., & Stewart, J. D. Isolation and Synthesis of One of the Most Central Cofactors in Metabolism: Coenzyme A. Org. Process Res. Dev. 2018, 23 (1), 19–30. 

  5. Westerveld, M., & Petracca, R. The mystery of crotonyl-CoA. Nat. Chem. 2024, 16, 1678. 

  6. Zhang, D., et al. Coenzyme A in Brain Biology and Neurodegeneration. Biomedicines 2025, 14 (1), 69. 

  7. Naquet, P., et al. Regulation of coenzyme A levels by degradation: the ‘Ins and Outs’. Prog. Lipid Res. 2020, 78, 101028. 

  8. Mignani, L., et al. Coenzyme a Biochemistry: From Neurodevelopment to Neurodegeneration. Brain Sci. 2021, 11 (8), 1031. 

  9. Baddiley, J., et al. Structure of coenzyme A. Nature 1953, 171, 76. 

  10. Lipmann, F., & Kaplan, N. O. Coenzyme for acetylation, a pantothenic acid derivative. J. Biol. Chem. 1947, 167, 869. 

  11. Gout, I. Coenzyme A: a protective thiol in bacterial antioxidant defence. Biochem. Soc. Trans. 2019, 47 (1), 469–476. 

  12. Semelak, J. A., et al. binding to coenzyme A. Arch. Biochem. Biophys. 2024, 763, 110202. 

  13. Heckmann, K., & Marquardt, T. Expanding the genetic and clinical spectrum of SLC25A42-associated disorders and testing of pantothenic acid to improve CoA level in vitro. JIMD Rep. 2024, 65 (6), 417–425. 

  14. Yu, Y., et al. Coenzyme A levels influence protein acetylation, CoAlation and 4′-phosphopantetheinylation: Expanding the impact of a metabolic nexus molecule. BBA - Mol. Cell Res. 2021, 1868 (4), 118965. 

  15. Srinivasan, B., et al. Extracellular 4’-phosphopantetheine is a source for intracellular coenzyme A synthesis. Nat. Chem. Biol. 2015, 11 (10), 784–792. 

  16. Sibon, O. C. M., & Strauss, E. Coenzyme A: to make it or uptake it? Nat. Rev. Mol. Cell Biol. 2016, 17 (10), 606. 

  17. Czumaj, A., et al. The Pathophysiological Role of CoA. Int. J. Mol. Sci. 2020, 21 (23), 9057. 

  18. Jones, A. E., et al. A Single LC-MS/MS Analysis to Quantify CoA Biosynthetic Intermediates and Short-Chain Acyl CoAs. Metabolites 2021, 11 (8), 468. 

  19. Sabari, B. R., et al. Intracellular Crotonyl-CoA Stimulates Transcription through p300-Catalyzed Histone Crotonylation. Mol. Cell 2015, 58 (2), 203–215. 

  20. Tsuchiya, Y., et al. Protein CoAlation: a redox-regulated protein modification by coenzyme A in mammalian cells. Biochem. J. 2017, 474 (14), 2489–2508. 

  21. Gout, I. Coenzyme A, protein CoAlation and redox regulation in mammalian cells. Biochem. Soc. Trans. 2018, 46 (3), 721. 

  22. Mignani, L., et al. Coenzyme a Biochemistry: From Neurodevelopment to Neurodegeneration. Brain Sci. 2021, 11, 1031. 

  23. Jeong, S. Y., et al. 4'-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN. EMBO Mol. Med. 2019, 11 (12), e10489. 

  24. Iuso, A., et al. Pantethine ameliorates dilated cardiomyopathy features in PPCS deficiency disorder in patients and cell line models. Commun. Med. 2025, 5 (1), 1017. 

  25. Iuso, A., et al. Mutations in PPCS, Encoding Phosphopantothenoylcysteine Synthetase, Cause Autosomal-Recessive Dilated Cardiomyopathy. Am. J. Hum. Genet. 2018, 102 (6), 1018–1030. 

  26. Heckmann, K., et al. Expanding the genetic and clinical spectrum of SLC25A42-associated disorders and testing of pantothenic acid to improve CoA level in vitro. JIMD Rep. 2024, 65, 417–425. 

  27. Spry, C., et al. Coenzyme A biosynthesis: an antimicrobial drug target. FEMS Microbiol. Rev. 2008, 32 (1), 56–106. 

Interested in Coenzyme A?

Explore our range of high-quality Coenzyme A products to support your research and applications

bottom of page